Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 8/20 | 0.71 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | GALR3 | O60755 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464272 | 1.00 | ADRB3 (0.71) | ADRB3ADRB2LMNAHIF1AADRB1 | |
| SCHEMBL5917160 | 1.00 | ADRB3 (0.71) | ADRB3ADRB2LMNAHIF1AADRB1 | |
| SCHEMBL4454700 | 0.86 | ADRB3 (0.55) | ADRB3ADRB2LMNAHIF1AADRB1 | |
| SCHEMBL5917146 | 0.86 | ADRB3 (0.55) | ADRB3ADRB2LMNAHIF1AADRB1 | |
| SCHEMBL4454692 | 0.86 | ADRB3 (0.55) | ADRB3ADRB2LMNAHIF1AADRB1 | |
| SCHEMBL2341389 | 0.83 | ADRB3 (1.00) | ADRB3ADRB2LMNAHIF1AADRB1 | |
| SCHEMBL3025239 | 0.83 | ADRB3 (1.00) | ADRB3ADRB2LMNAHIF1AADRB1 | |
| SCHEMBL13959128 | 0.83 | ADRB3 (1.00) | ADRB3ADRB2LMNAHIF1AADRB1 | |
| SCHEMBL2341392 | 0.83 | ADRB3 (0.74) | ADRB3ADRB2LMNAHIF1AADRB1 | |
| SCHEMBL6743617 | 0.82 | ADRB3 (0.72) | ADRB3ADRB2LMNAHIF1AADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012161-A9 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | US | disclosed |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | MICHEL MARTIN | 2007-06-07 | — | — | US | disclosed |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| US-20050261369-A1 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| US-20050119239-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-02 | — | — | US | disclosed |
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101607-A1 | Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB2 3/4885LMNA 2502/4885 |
| US-20050261369-A1 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 1918/4885 |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 1686/4885 |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 2025/4885 |
| US-20050119239-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 1785/4885 |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 1351/4885 |
| US-20090012161-A9 | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 1918/4885 |
| US-20070129435-A1 | Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885LMNA 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.